Lyell Immunopharma, Inc. LYEL
14.82 USD +0.52 (+3.64%)
As ofNov 16, 2026, 3:23 PM EST
13.91 Day range 14.86
7.20 52-week range 45.00
- YTD
- -51.85%
- 1 year
- -12.46%
News
zacks.com Wall Street Analysts See a 148.25% Upside in Lyell Immunopharma (LYEL): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 148.3% in Lyell Immunopharma (LYEL). While the effectiveness of this highly sought-after metric is…benzinga.com HC Wainwright & Co. Maintains Buy on Lyell Immunopharma, Lowers Price Target to $39 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $45 to $39.
seekingalpha.com Lyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript Lyell Immunopharma, Inc. ( LYEL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 4:00 PM EST Company Participants Lynn Seely - Principal Executive Officer, President, CEO & Director…benzinga.com Lyell Immunopharma Q3 EPS $(1.86) Beats $(2.06) Estimate, Sales $3.000K Beat $2.333K Estimate Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(2.06) by 9.71 percent. This is a 12.68 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Curis (NASDAQ:CRIS) shares moved upwards by 61.8% to $1.16 during Wednesday's regular session. The market value of their outstanding shares is at $1.7 million. Lyell Immunopharma…benzinga.com Lyell Immunopharma Announces ~$80M Private Placement Of 7.4M Shares At $10.77/Share The investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors.The financing…
benzinga.com Lyell Immunopharma Announces That Two Abstracts Featuring Updated Clinical Data For Rondecabtagene Autoleucel Have Been Accepted To The American Society Of Hematology Meeting, December 12–15; Ronde-Cel Achieved 91% Overall Response Rate And 77% Complete Response Rate Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients…
